drugset / Trial / NCT03587194
Evaluation of Add on Enstilar in Patients Using Otezla for Psoriasis
Phase 4
Completed
50 enrolled
Psoriasis Treatment Center of Central New Jersey
Celgene Corporation · collab
NaSingle-groupOpen-labelTreatment
Summary
Add-on Enstilar to Otezla therapy.
Timeline
- Start
- 2018-07-23
- Primary completion
- 2019-07-01
- Completion
- 2019-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Apremilast | Small molecule | 30 mg | — |